

# Sustainability Report

# 2023



Mitsubishi Tanabe Pharma



MITSUBISHI  
CHEMICAL  
GROUP

## Contents

Editorial Policies	1	<b>Society</b>	
Mitsubishi Tanabe Pharma's Sustainability	2	Together with Patients and Healthcare Professionals	
Materiality	3	Research & Development	50
Stakeholder Engagement	10	Stable Supply	52
		Manufacturing Pharmaceuticals that are Secure, Safe, and Convenient to Use	56
		Information Provision	59
		Drug Safety / Quality Assurance	67
		Solving Issues Related to Improving Access to Healthcare	71
		Together with Employees	
		Human Resources Development	76
		Promoting Diversity & Inclusion	80
		Work-Style Innovation	87
		Occupational Health and Safety	90
		Together with Business Partners	
		Promotion of CSR Procurement	104
		Together with the Local Community	
		Corporate Citizenship Policy	107
		Contributions to Medical Care and Welfare	109
		Development of Science and Technology	119
		Contributions to the Environment	120
		Promotion of Local Communities	122
		Activities Addressing Social Needs	127
		Other Related Information	
		External Evaluations	131
		Data	133
		GRI Standard Comparative Table	153
		Explanation of Terms	160
		Company Overview 2023	162
<b>Management</b>			
Code of Conduct	11		
Respect for Human Rights	12		
R&D Ethics	16		
Compliance	18		
Risk Management	20		
Promotion of Fair Operating Practices	22		
<b>Environment</b>			
Environmental Management	26		
Targets & Initiatives	30		
Climate Change Initiatives	34		
Water Resource Initiatives	39		
Initiatives to Reduce Waste and Reuse Resources	40		
Initiatives to Prevent Pollution	42		
Biodiversity Initiatives	45		
Environmental Accounting	48		



# Editorial Policies

This website is intended to provide the Group's stakeholders, including patients, healthcare professionals, local communities, and employees, with information about major sustainability initiatives implemented by the Group in fiscal 2022. Specific initiatives implemented in accordance with the Company's philosophy are presented in line with management, the environment, and society. Additionally, it also features descriptions of the Mitsubishi Chemical Group (the MCG Group) initiatives and activities undertaken under the "One Company, One Team" system.

The Sustainability Report 2023 PDF version, which contains the same content as disclosed on this website, can be downloaded from [the Sustainability Report archive page](#).

[Explanations of medical and pharmaceutical terms](#) appearing in this report have been provided to foster a wider understanding of the report's content.

<b>Applied Guidelines</b>	<ul style="list-style-type: none"><li>• Global Reporting Initiative (GRI) Sustainability Reporting Standard;</li><li>• Environmental Reporting Guidelines, 2018 version, published by the Ministry of the Environment of Japan</li></ul>
<b>Period covered</b>	April 1, 2022, to March 31, 2023 (The report includes examples of activities from April 2022 and thereafter)
<b>Issue timing</b>	September 2023 (Previous report: September 2022; next report: September 2024)
<b>Scope of reporting</b>	Mitsubishi Tanabe Pharma and consolidated subsidiaries in Japan and overseas. (The scope of reporting could differ in accordance with the examples being reported.)
<b>Contact information</b>	> <a href="#">Contact Us</a>